TCT 2024 - TCTMD.com
Oct 27, 2024 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
TCTMD - tctmd.com
TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.
Cheaper Version of Tirzepatide for Weight Loss Now Available, …
Aug 28, 2024 · The manufacturer is selling single-dose vials of the drug via its online pharmacy at around $400 to $500 for a 4-week supply.
FDA Approves Varipulse Pulsed-Field Ablation System for AF
Nov 7, 2024 · The US Food and Drug Administration has approved the Varipulse pulsed-field ablation (PFA) system for the treatment of drug-refractory paroxysmal atrial fibrillation (AF), device manufacturer Johnson & Johnson MedTech announced today.
TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid ...
Oct 30, 2024 · Susheel Kodali, MD (NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY), who presented the results during the late-breaking clinical trials session at TCT 2024, emphasized that they were able to show the “near elimination of TR, which was sustained out to 1 year.”The 30-day and 6-month results in the first 150 patients were previously published, and reported by ...
Lp(a) Can Vary Over Time in ASCVD Patients With High Baseline …
Dec 13, 2024 · Serial measurements of lipoprotein(a) can change by as much as 10% over time for about one in five patients with atherosclerotic cardiovascular disease (ASCVD) and high Lp(a) concentration at baseline, according to new data from the placebo arm of OCEAN(a)-DOSE.
Varipulse Pulsed-Field Ablation System Safe, Effective in Pivotal Trial
Sep 30, 2024 · Pulsed-field ablation (PFA) with a system encompassing the Varipulse catheter and Trupulse generator with integrated 3D electroanatomic mapping (all Biosense Webster) safely and effectively treats patients with paroxysmal atrial fibrillation (AF), results of …
QFR No Match for FFR in Guiding Revascularizations: FAVOR III …
Oct 30, 2024 · WASHINGTON, DC—As a guide for deciding whether to revascularize patients with intermediate coronary stenoses, quantitative flow ratio (QFR) isn’t able to match fractional flow reserve (FFR) in terms of 12-month clinical outcomes, data from the large, randomized, FAVOR III Europe trial show.
Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD
Nov 16, 2024 · CHICAGO, IL—Intensively treating systolic blood pressure below 120 mm Hg reduces the risk of major cardiovascular events over 4 years in patients with type 2 diabetes and hypertension compared with the standard protocol of less than 140 mm Hg, according to …
Slides | tctmd.com
Apr 14, 2024 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.